We focus on high unmet need areas in cardio-metabolic disorders including diabetes and obesity
| Asset | MOA/Target | Indication | Discovery | Pre Clinical | Phase I | Phase II | Phase III |
| RT-1001 (Small Molecule) |
GLP-1R agonist | DM-2 / Obesity |
Discovery Pre-clinical Phase I Phase II Phase III |
||||
|---|---|---|---|---|---|---|---|
| RT-2001 (Small Molecule) |
GIPR agonist | DM-2 / Obesity |
Discovery Pre-clinical Phase I Phase II Phase III |
||||
| RT-3001 (Small Molecule) |
GIPR antagonist | Obesity |
Discovery Pre-clinical Phase I Phase II Phase III |
||||
| RT-4001 (Small Molecule) |
GLP-1R agonist / GIPR agonist | DM-2 / Obesity |
Discovery Pre-clinical Phase I Phase II Phase III |
||||
| RT-5001 (Small Molecule) |
GLP-1R agonist / GIPR antagonist | Obesity |
Discovery Pre-clinical Phase I Phase II Phase III |
||||
| RT-6001 (Small Molecule) |
Apelin agonist | DM-2 / Obesity |
Discovery Pre-clinical Phase I Phase II Phase III |
||||
| RT-7001 (Small Molecule) |
GLP-1 agonist / Apelin agonist | DM-2 / Obesity |
Discovery Pre-clinical Phase I Phase II Phase III |
||||